Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Post-Stenting Antiplatelet Trial Gains $1.5 Million Boost From FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Study aims to identify optimum duration of anti-clotting drugs for stent patients; enrollment targeted at 20,000 patients.
Advertisement

Related Content

Antiplatelets In The Wilderness After Mixed Results From DAPT Study
Effient Labeling Could Give Edge Against Plavix Through Pharmacogenetics
Effient Labeling Could Give Edge Against Plavix Through Pharmacogenetics
High Hopes For Stent Antiplatelet Therapy Trial

Topics

Advertisement
UsernamePublicRestriction

Register

PS069688

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel